Why this might matter to you
No gene gets more wellness marketing per unit of biology than MTHFR. It's sold as a hidden defect, a reason to buy methylated everything, and the secret behind a long list of unrelated complaints. Consider this your guide, grounded in fact, to the nuance behind whatever else you may read.
MTHFR is the gene that helps your body turn the folate (vitamin B9) you eat into the active form your cells use. Two common changes in it get almost all of the attention, and the supplement market likes to sell them as a matched set. C677T (rs1801133) is the famous one. A1298C (rs1801131) is the other half of the pitch, the variant invoked to explain whatever C677T did not already cover. You carry zero, one, or two copies of each. Each is a normal piece of human variation, not a diagnosis. This article covers both: what each one is, what the published evidence actually reports, and the one place they genuinely interact.
What they do and don't change
For C677T, the established, measurable part is specific: in people who carry two copies, published studies link the pattern to higher levels of a blood marker called homocysteine, and that link is strongest when folate or B12 intake is low. Each copy slows the enzyme down a little. What the variant doesn't do is tell you something is wrong with you, or that you need any particular supplement. The effect in the literature is a tendency measured across groups, not a verdict about any single person, and for someone eating an ordinary folate-containing diet it changes far less than the supplement market implies.
A1298C does even less on its own. It sits in a different region of the MTHFR gene than C677T, and on its own it is tied much less tightly to the homocysteine rise that C677T is known for. The one scenario where it earns attention is compound heterozygosity: one copy of A1298C together with one copy of C677T. What A1298C does not do is act as a second independent defect that doubles a methylation problem. The one published figure that looks at the compound pattern and a disease outcome did not reach statistical significance, which is a detail the protocols built on this variant tend to leave out.
What the genotypes are
Both variants are read at a single position each on chromosome 1, and a raw DNA file reports two letters at each spot.
C677T is read at rs1801133. The reference genotype (G,G) carries no C677T change and shows normal enzyme activity at this position. One copy (G,A) is the heterozygous form. Two copies (A,A) is the homozygous form, often written TT.
A1298C is read at rs1801131. The reference genotype (T,T) carries no A1298C change and shows standard enzyme activity at this position. One copy (T,G) is the heterozygous form. Two copies (G,G), sometimes written 1298CC, carry the variant on both chromosomes. The name "A1298C" follows a standard DNA-naming convention, pointing to the change at nucleotide position 1298.
In the Varia Genome Catalog both sit in the Methylation and Detoxification module, under Metabolism and Longevity, which covers folate and one-carbon metabolism, the pathway that clears homocysteine and supports methylation reactions throughout the body.
Both are common, and the numbers settle the point. In gnomAD reference data the C677T (T) allele appears at roughly 32 percent globally and roughly 34 percent in the non-Finnish European population, with more than 80,000 homozygous individuals on record. The A1298C allele appears at roughly 31 percent globally and in the non-Finnish European population, with more than 70,000 homozygous individuals recorded. A genotype shared by tens of thousands of catalogued people is variation, not defect.
What the literature reports
The enzyme these variants encode converts 5,10-methyleneTHF into 5-methylTHF, the active folate form the body uses to recycle homocysteine back to methionine, which is why this pathway is studied alongside folate and B vitamin status PMID 20814827.
C677T was first characterized as a common missense mutation that makes the MTHFR enzyme heat-sensitive and lowers its activity, and homozygous individuals showed significantly elevated plasma homocysteine compared with non-homozygous individuals PMID 7647779. The Varia Genome Catalog summarizes the activity reduction as roughly 65 percent of normal for one copy and roughly 30 percent of normal for two copies, with mildly elevated homocysteine most relevant when folate or B12 availability is low PMID 30693532.
A1298C's documented effect on that same pathway, taken alone, is modest, and it is tied to homocysteine far less strongly than C677T. Its most cited result comes from a case-control study of neural tube defects, which reported that combined heterozygosity, one A1298C allele together with one C677T allele, was associated with neural tube defect risk at an odds ratio of 2.04, seen in 28 percent of the 86 patients versus 20 percent of the 403 controls PMID 9545395. Its 95 percent confidence interval ran from 0.9 to 4.7. That interval crosses 1.0, which means the data are consistent with no effect at all, and the result did not reach conventional statistical significance. A single study with a wide, boundary-crossing interval is where a finding starts, not where it's settled.
One further consideration for A1298C is a possible effect of the homozygous form on BH4 (tetrahydrobiopterin), a cofactor in serotonin, dopamine, and nitric oxide synthesis. This is the least-cited part of the reliable record - a mechanistic possibility rather than an established, replicated result. Varia will continue to monitor the landscape as the science develops.
Compound heterozygosity: the one place they interact
The configuration worth understanding is carrying one copy of C677T (rs1801133) and one copy of A1298C (rs1801131) at the same time. This is where A1298C becomes most interpretively relevant, which is why the Varia Genome Scanner reads both positions before describing either. Even here, the strongest single figure for a disease outcome, the 2.04 odds ratio above, crossed the line into no-effect territory PMID 9545395. The compound pattern is worth knowing about; it is not a verdict.
What Varia does with these variants
Varia reads your raw DNA file on your own device and, where your file includes rs1801133 and rs1801131, resolves your genotypes locally. The results appear under Metabolism and Longevity, in the Methylation and Detoxification module, with the matching Varia Genome Catalog summary and the linked, peer-reviewed citations above. Because A1298C is most meaningful next to C677T, the scanner reads both and reports the compound pattern when both are present. We describe what the published evidence reports. We don't tell you what to take or do, and we won't carry a claim the Varia Genome Catalog can't cite. Our intention is to hand you the facts as they stand, without sugarcoating and without fear-mongering.
Questions and answers
Is one copy of C677T the same as two?
No. The Varia Genome Catalog describes one copy (G,A) as a modest reduction in enzyme activity and two copies (A,A, also called TT) as a larger reduction, with the homozygous form being the configuration most associated with elevated homocysteine in the studies above PMID 7647779.
Is A1298C as significant as C677T?
Not on its own. The Varia Genome Catalog ties A1298C much less tightly to elevated homocysteine than C677T, and its best-documented role is in the compound pattern, one A1298C allele alongside one C677T allele PMID 9545395. Read in isolation, a single A1298C result carries less weight than a C677T result.
What is compound heterozygosity?
It means carrying one copy of C677T (rs1801133) and one copy of A1298C (rs1801131) at the same time. The Varia Genome Catalog flags this combination as the configuration where A1298C becomes most interpretively relevant, which is why the Varia Genome Scanner reads both positions before describing either.
Does either variant mean something is wrong with me?
No. Both are common, tens of thousands of people carry two copies of each, and their measured effects on their own are small. They describe tendencies studied across groups, not a diagnosis for an individual.
The short version
What is established: C677T and A1298C are two common, distinct variants in the MTHFR gene. Two copies of C677T lower enzyme activity, and homocysteine rises modestly in homozygous individuals when folate or B12 is low PMID 7647779 PMID 20814827. A1298C, on its own, is tied only weakly to the same pathway.
What is not established: any role for these variants in the broader conditions marketed against them, any genotype-specific supplement need beyond ordinary folate intake, and any independent, significant disease effect for A1298C alone. The one disease-association figure here, for the compound pattern, crossed the line into no-effect territory PMID 9545395.
To check your own genotypes, see whether you carry the compound pattern, and read the cited, peer-reviewed evidence behind each call, use the Varia Genome Scanner. It reads your raw DNA file in your browser and checks it for rs1801133 and rs1801131 along with the rest of the Varia Genome Catalog. Array files like 23andMe and AncestryDNA cover most of the catalog but not all, so the scan tells you whether yours is included, and your file never leaves your device.